Massachusetts General Hospital
The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.
While there are many potential therapeutics being evaluated for Alzheimer's disease and related dementias (ADRD), there is currently no known cure for ADRD and its origin and pathophysiology are still not well understood. However, the association of fibrin with ADRD is becoming increasingly clearer. Up to now it was not possible to quantify brain fibrin in vivo to better elucidate its role in ADRD, but recently, 64Cu-FBP8 was proposed as a tool to detect thrombus anywhere in the body. This unique tool will allow us to non-invasively assess brain fibrin levels in at-risk and ADRD subjects. The…
Inclusion Criteria: * Age between 55 and 90 years * Ability to provide informed consent * Specific to healthy volunteers: no history of ADRD * Specific to ADRD subjects: clinical diagnosis of AD - either amnestic or atypical, clinical severity ranging from MCI to moderate dementia (CDR 0.5-2.0), MMSE score greater than or equal to 15 and/or MOCA greater than or equal to 12 * Specific to BAnD subjects: referred through the Brain Aging and Dementia (BAnD) research registry Exclusion Criteria: * MR contraindications such as: electrical implants such as cardiac pacemakers or perfusion pumps; fe…
PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol
Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
Arctuva estimate
Verify or correct the compensation shown for this listing.